NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
企業コードNURO
会社名NeuroMetrix Inc
上場日Jul 22, 2004
最高経営責任者「CEO」Dr. Shai N. Gozani, M.D., Ph.D.
従業員数13
証券種類Ordinary Share
決算期末Jul 22
本社所在地1000 Winter Street
都市WALTHAM
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02451
電話番号17818909989
ウェブサイトhttps://www.neurometrix.com/
企業コードNURO
上場日Jul 22, 2004
最高経営責任者「CEO」Dr. Shai N. Gozani, M.D., Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし